Jinlu Cai

Title: Jinlu Cai - Innovator in Therapeutic Agents

Introduction

Jinlu Cai is a prominent inventor based in Zhejiang, China. He has made significant contributions to the field of therapeutic agents, particularly in the development of innovative treatments involving nucleic acids and CAR-modified immune cells. His work is pivotal in advancing cancer therapies.

Latest Patents

Jinlu Cai holds a patent for "Therapeutic agents comprising nucleic acids and CAR-modified immune cells, and uses thereof." This patent describes a therapeutic agent that includes a nucleic acid designed to be introduced into tumor or cancer cells. The agent comprises a first composition, which includes a nucleic acid coding sequence for a labeling polypeptide, and a second composition that consists of chimeric antigen receptor modified immune cells. This innovative therapeutic agent aims to achieve a synergistic therapeutic effect.

Career Highlights

Jinlu Cai is associated with Hangzhou Converd Co., Ltd., where he continues to work on groundbreaking research in the field of immunotherapy. His expertise in developing therapeutic agents has positioned him as a key figure in the industry.

Collaborations

Jinlu Cai collaborates with notable colleagues, including Fang Hu and Can Chen. Their combined efforts contribute to the advancement of innovative therapeutic solutions.

Conclusion

Jinlu Cai's work in the development of therapeutic agents represents a significant advancement in cancer treatment. His innovative approach and collaboration with talented colleagues continue to drive progress in the field.